SUMMARY Twenty patients satisfying standard clinical criteria for Alzheimer's disease (AD) and six age-matched normal controls were studied using 9'Tc hexamethyl-propyleneamine oxime and single photon emission tomography. The AD patients had lower regional cerebral blood flow (rCBF) in the temporal and posterior parietal lobes compared to controls. AD patients with apraxia and aphasia had lower rCBF in the lateral temporal and posterior parietal lobes than AD patients without these features. Within the AD group, correlations were found between neuropsychological tests and rCBF: praxis correlated with posterior parietal activity, memory with left temporal lobe activity and language with activity throughout the left hemisphere.
Neuroimaging has developed rapidly in the past few years with the introduction of x-ray computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and single photon emission tomography (SPET). CT and MRI offer unique anatomical information while PET and SPET reveal physiological functions such as cerebral blood flow and cerebral metabolism. 9 'Tc hexamethyl-propyleneamine oxime (HMPAO) is a new radiopharmaceutical which crosses an intact blood brain barrier and is trapped inside functioning cells in proportion to cerebral blood flow (CBF). '2 Alzheimer's disease (AD) affects between 6 to 7% of the population over the age of 653 and represents a major health issue. The cause is not known and no effective treatment exists. CT studies of subjects with AD have demonstrated abnormalities including cerebral atrophy and ventricular enlargement.4 MRI has demonstrated white matter lesions and abnormal spin lattice relaxation times.5 PET scanning has shown defects in metabolism in temporal and parietal lobes6 and similar results have been found using SPET.75 Although in some ways PET is the ideal way of studying functional imaging the technique is extremely expensive and requires a large highly trained technical staff.
The majority of SPET studies in dementia have attempted to describe the scan appearances in different types of dementia and to assess the ability of the HMPAO in the brain and is the first to determine how it relates to a number of clinical and neuropsychological characteristics of a group of AD patients.
Subjects and methods
Subjects were selected from a series ofconsecutive referrals to the Memory Clinic at the Maudsley Hospital. All underwent a standard assessment including history, physical and mental state examination, blood tests and CT.9 All satisfied current rigorous criteria for AD." No patient had clinical signs of cerebellar dysfunction. Controls, who had no signs or symptoms of dementia, were selected from the relatives of patients chosen for the study. On the basis of clinical examination the AD patients were allocated to one of two groups: those in whom amnesia was the prominent feature, and those in whom significant aphasia and/or apraxia were also evident. The investigation ofAlzeheimer's disease with single photon emission tomography Figure 1 shows the areas in which the regions of interest were measured. These were averaged to calculate the mean counts per voxel corresponding to each cortical region studied. This method fagh was also applied to at least three contiguous slices of the cerebellum.
The counts per voxel of each cortical area were divided by the counts per voxel found in the cerebellar hemisphere with the highest average count, to determine the activity ratio (cerebrum/cerebellum).
These analyses were performed by one of us (DCC) blind to the clinical diagnosis or subgroup.
The ratios for AD patients were compared with those obtained from the subjects of the control group. Results were analysed using non-parametric statistics with an SPSS package. '4 Results Twenty patients (13 females, seven males) and six controls (three females, three males) were scanned. All subjects were right handed. No adverse reactions to the procedure occurred. The relationship between these metabolic deficits and clinical features has been less widely studied. Generally, it has been found that the more severe the dementia syndrome the lower the activity.'7 Specifically, decreased activity has been shown in the right parietal lobe in subjects with apraxia and in the left tempora parietal lobe in those with aphasia.2' No specific lesion was associated with memory loss. In this study there is evidence that amnesia is associated with decreased rCBF in the temporal lobe, apraxia with reduced rCBF to the parietal lobe and aphasia with reduced rCBF throughout the left hemisphere.
Sub-classification of AD has much empirical support from a neurochemical,22 neuropathological23 and clinical24 viewpoint. Younger cases tend to have a more severe illness with prominent visuo-spatial abnormalities. Studies using PET suggest that early cases show regional decrements in the parietal lobe.25 Using HMPAO, posterior reductions were shown more commonly in AD subjects with aphasic and apraxic disorders compared to those without. 8 The present study confirms the differences in these two groups; those with visuo-spatial disorder had decreased rCBF in the lateral temporal and posterior parietal lobe. In addition, an early age of onset correlated with lower activity in the left posterior parietal lobe showing that younger age ofonset results in more severe damage to this region. Right/left asymmetries have been found in studies of AD patients using both PET26 and SPET.8 The cause of this is not known but it is more common in AD patients than in controls. It has been found that late onset AD is associated with deficits of the left side whereas early onset AD is associated with deficits on the right. 28 Future research employing SPET should not be limited. to replicating the now well-documented differences in rCBF between patients with AD and normal controls but should also include investigation of the effects of cerebral activation tasks. New radiopharmaceuticals may be developed to image receptor systems such as in the case ofthe muscarinic receptor26 which has particular relevance to AD in view of the cholinergic hypothesis.
